Physician profile
Cini John
NPI 1528590288
$21,832.20
in general payments reported to CMS, 2019-2025
62 companies · $4,834 in 2025
The $4,834 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,690 · 2022: $4,120 · 2023: $3,510 · 2024: $4,679 · 2025: $4,834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,847.83 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,791.76 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,107.72 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,846.12 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,321.14 | 2021-2025 | Evenity, Prolia, Prolia |
| Glaxosmithkline, LLC. | $1,208.64 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,155.44 | 2021-2025 | Jardiance, Stiolto Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $1,138.56 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,111.26 | 2021-2025 | Xifaxan, Relistor |
| Lilly USA, LLC | $805.73 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Mylan Specialty L.P. | $640.89 | 2021-2024 | Yupelri |
| Gilead Sciences, INC. | $505.61 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $483.80 | 2021-2023 | |
| Radius Health, INC. | $456.88 | 2021-2025 | Tymlos |
| Corcept Therapeutics | $391.11 | 2023-2025 | Korlym |
| Amarin Pharma, INC. | $371.00 | 2021-2023 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cini John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.